News | April 17, 2026
NIFTY Pharma shows stable trend amid cautious market sentiment
Muted movement reflects consolidation phase as investors await earnings triggers
Muted movement reflects consolidation phase as investors await earnings triggers
IMCD India’s innovative formulations bring the Skinification trend to life with cutting-edge solutions across beauty and personal care
Combination shows consistent benefit across prespecified post-progression outcomes
Investigational cell therapy bemdaneprocel continues to be well tolerated with no major safety issues in all 12 participants in low and high dose cohorts through 18 months
The survey data presented in “The State of the Biopharmaceutical Industry 2024” report reveals that N=21 (18%) of industry professionals were convinced that CGT will dominate as the most important trend in pharma next year
RNA, cell & gene therapies, artificial intelligence, CRISPR and oncology-related deals dominate the landscape
While overall survival data remain immature, the results pointed to a favourable trend.
The trial results are for the pharma powerhouse's RET-targeted therapy Retevmo (selpercatinib)
This alliance, covering up to 12 antibody drugs, highlights the growing trend of large-scale collaborations between Chinese biotech firms and global pharmaceutical giants
This marks one of the most closely watched oncology readouts at this year’s medical congress
Subscribe To Our Newsletter & Stay Updated
